Role of Additional Mutations outside the YMDD Motif of Hepatitis B Virus Polymerase in l(−)SddC (3TC) Resistance
Open Access
- 1 May 1998
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 55 (10) , 1567-1572
- https://doi.org/10.1016/s0006-2952(98)00050-1
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Lamivudine resistance inimmunocompetent chronic hepatitis BJournal of Hepatology, 1997
- Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudineLiver International, 1997
- Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantationThe Lancet, 1997
- Selection of Mutations in the Hepatitis B Virus Polymerase During Therapy of Transplant Recipients With LamivudineHepatology, 1996
- Hepatitis B virus-induced hepatocellular carcinoma: possible roles for HBxTrends in Microbiology, 1996
- A Preliminary Trial of Lamivudine for Chronic Hepatitis B InfectionNew England Journal of Medicine, 1995
- HIV resistance to reverse transcriptase inhibitorsBiochemical Pharmacology, 1994
- High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptaseAntimicrobial Agents and Chemotherapy, 1993
- Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues.Proceedings of the National Academy of Sciences, 1991
- Hepatitis B VirusScientific American, 1991